Who owns Lakefront Biotherapeutics NV?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of LKFT from SEC Form 13F filings across 95 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 95 institutions disclosed 33.6M shares of Lakefront Biotherapeutics NV worth $1.00B — about 50.9% of shares outstanding; the largest disclosed holder is GILEAD SCIENCES, INC.. Source: SEC Form 13F filings, parsed by EvidInvest.
95
13F holders
$1.00B
value, 2026 filers
50.9%
of shares outstanding (33.6M sh)
23
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of LKFT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 16.7M | $501.3M | 34.2% | 25.4% | 0.0% |
| 2 | TANG CAPITAL MANAGEMENT LLC | 4.0M | $118.2M | 5.4% | 6% | +5.3% |
| 3 | Madison Avenue Partners, LP | 3.5M | $104.3M | 4.1% | 5.3% | +2.0% |
| 4 | Prosight Management, LP | 2.0M | $59.3M | 11.5% | 3% | -2.2% |
| 5 | EcoR1 Capital, LLC | 1.7M | $49.4M | 2.2% | 2.5% | 0.0% |
| 6 | PERCEPTIVE ADVISORS LLCNEW | 1.2M | $36.8M | 0.6% | 1.9% | new |
| 7 | UBS Group AG | 647,520 | $19.2M | 0.0% | 1% | +285.1% |
| 8 | DME Capital Management, LP | 482,746 | $14.3M | 0.4% | 0.7% | 0.0% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 424,700 | $12.6M | 0.0% | 0.6% | +4.1% |
| 10 | BlackRock, Inc. | 394,013 | $11.7M | 0.0% | 0.6% | +16.5% |
| 11 | D. E. Shaw & Co., Inc. | 325,660 | $9.7M | 0.0% | 0.5% | +64.6% |
| 12 | CITADEL ADVISORS LLC | 312,634 | $9.3M | 0.0% | 0.5% | +253.9% |
| 13 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIPNEW | 311,631 | $9.2M | 0.0% | 0.5% | new |
| 14 | Point72 Asset Management, L.P. | 232,756 | $6.9M | 0.0% | 0.4% | -13.7% |
| 15 | TWO SIGMA INVESTMENTS, LP | 167,218 | $5.0M | 0.0% | 0.3% | +104.6% |
| 16 | GOLDMAN SACHS GROUP INC | 140,490 | $4.2M | 0.0% | 0.2% | +148.3% |
| 17 | DAFNA Capital Management LLC | 130,175 | $3.9M | 0.8% | 0.2% | 0.0% |
| 18 | ALPS ADVISORS INC | 88,253 | $2.6M | 0.0% | 0.1% | +34.7% |
| 19 | MARSHALL WACE, LLP | 78,456 | $2.3M | 0.0% | 0.1% | +142.2% |
| 20 | Qube Research & Technologies LtdNEW | 65,896 | $2.0M | 0.0% | 0.1% | new |
| 21 | HRT FINANCIAL LP | 50,789 | $1.5M | 0.0% | 0.1% | +193.1% |
| 22 | AMERICAN CENTURY COMPANIES INC | 41,367 | $1.2M | 0.0% | 0.1% | +1.4% |
| 23 | MORGAN STANLEY | 40,823 | $1.2M | 0.0% | 0.1% | +8.3% |
| 24 | BAROMETER CAPITAL MANAGEMENT INC. | 40,800 | $1.2M | 0.3% | 0.1% | 0.0% |
| 25 | Schonfeld Strategic Advisors LLC | 38,731 | $1.1M | 0.0% | 0.1% | +18.8% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.